Predictive Cancer Model Clinical Trial
— MTGOfficial title:
Development and Clinical Utility of a New Method to Identify Patients With Risk of Recurrent Colorectal Lesions and Personalization of Their Surveillance Based on Mutation Burden and Clinical-pathological Phenotype
It is known that the development of colorectal adenoma is dependent on the appearance of somatic mutations in protooncogenes and tumor suppressor genes. Based on our previous mutation analyses of 120 patients with high-risk adenoma removed by enbloc resection with subsequent colonoscopy after 1 year, there is a correlation between mutation in exon 7 of the TP53 gene and risk of early metachronous lesions development. The results also indicate that mutation phenotype (mutation profile and burden) of all lesions detected on index colonoscopy can determine risk of metachronous lesions. As not all synchronous lesions were analyzed and the surveillance colonoscopy interval was less than 3 years, this assumption could not be confirmed. In this study it is planned to perform mutation analysis of all synchronous lesions in 200 patients and correlate the data with appearance of metachronous lesions after 1, 3 and 5 years. Moreover, the mutation profile of all metachronous lesions developed during the 5 years of surveillance will be determinated and compared with mutation profile of index lesions from the same localization to verify their common biological origin. This all could help personalize the surveillance program in terms of reduction of the burden on the patient and endoscopic workplaces and risk of developing colorectal cancer in a particular patient.
Status | Recruiting |
Enrollment | 200 |
Est. completion date | December 31, 2026 |
Est. primary completion date | December 31, 2026 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - Colorectal polyp larger than 10mm removed by colonoscopy therapeutic method (EPE, EMR, ESD) - Signed informed consent with the study and with colonoscopy Exclusion Criteria: - FAP, HNPCC and other hereditary CRC syndromes probands - Colonoscopy contraindication - Severe acute inflammatory bowel disease - Severe comorbidities; likely non-compliance of the patient |
Country | Name | City | State |
---|---|---|---|
Czechia | Military University Hospital | Prague |
Lead Sponsor | Collaborator |
---|---|
Military University Hospital, Prague |
Czechia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Mutational phenotype of patient. | Correlation of clinical and histopathological parameters with mutational phenotype of patient. | 5 years | |
Other | Metachronous lesions | Correlation of patient's mutational phenotype with an occurrence of metachronous lesion/s during surveillance period. | 5 years | |
Other | Similarity of the mutation profile of lesions found in the same area | Analysis of the similarity of the mutation profile of lesions found in the same / close areas of the colorectum. | 5 years | |
Primary | Development and Clinical Utility of a New Method to Identify Patients With Risk of Recurrent Colorectal Lesions and Personalization of Their Surveillance Based on Mutation Burden and Clinical-pathological Phenotype | To identify patients with high risk of metachronous colorectal lesions and try to design and optimal intervals of surveillance colonoscopies, especially in the high-risk group of patients, using mutation and clinical-pathologic phenotype. | 5 years | |
Secondary | Determination of the mutation profile colorectal lesions | Determination of the mutation profile and mutation burden in 200 patients based on examination of all their index and synchronous lesions found during index colonoscopy using an established PCR/DCE-based heteroduplex method. | 5 years | |
Secondary | Mutational profil of colorectal lesions | Clinical and histopathological evaluation and mutational profiling of all metachronous lesions found during five-year surveillance period. | 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06023966 -
A Clinical Prospective Study to Validate a Risk Scoring Model for the HMGC After Curative Surgery
|
||
Recruiting |
NCT04535466 -
Diagnosis Predictive Modle for Dense Density Breast Tissue Based on Radiomics
|
||
Recruiting |
NCT03280134 -
A Prospective Validation Cohort Study of a Prediction System on nSLN Metastasis in Early Breast Cancer
|
N/A | |
Recruiting |
NCT03253107 -
Predicting Biomarker of Gastric Cancer Chemotherapy Response
|
||
Recruiting |
NCT06364371 -
Dynamic Multi-omics Integration Model to Predict Neoadjuvant Therapy Response in Locally Advanced Rectal Cancer
|
||
Recruiting |
NCT05997147 -
A Preoperative Model to Predict the Lymphovascular Invasion in Pancreatic Ductal Adenocarcinoma
|
||
Active, not recruiting |
NCT05973331 -
Prospective Validation of an EHR-based Pancreatic Cancer Risk Model
|
||
Recruiting |
NCT05338073 -
KM3D Multicenter Cancer Consortium: Predicting Patient Response Using 3D Cell Culture Models
|
||
Recruiting |
NCT06391892 -
Liquid Biopsy (ctDNA) Guided Treatment in Localized Pancreatic Cancer: Neoadjuvant CTX vs. Upfront Surgery
|
Phase 3 | |
Recruiting |
NCT06202404 -
Predicting Tumor Metastasis by Employing a Target Organ/Primary Lesion Fusion Radiomics Model
|
||
Completed |
NCT06411015 -
Prognostic Evaluation Prediction Model Survival Spinal Epidural Metastases
|
||
Completed |
NCT04079283 -
Radiomics of Immunotherapeutics Response Evaluation and Prediction
|
||
Completed |
NCT06092918 -
Generation and Validation of Predictive Models for Localized Prostate Cancer Treated With External Radiotherapy.
|
||
Recruiting |
NCT06339307 -
A Prospective Clinical Study to Validate a Preoperative Risk Scoring Model for LNM in GC Patients
|
||
Recruiting |
NCT04185779 -
COLO-COHORT (Colorectal Cancer Cohort) Study
|
||
Active, not recruiting |
NCT06074029 -
Exploratory Study on the Therapeutic Effect Prediction Model of Advanced BTC Immunotherapy
|
Phase 1/Phase 2 | |
Recruiting |
NCT05741944 -
The Value of a Risk Prediction Tool (PERSARC) for Effective Treatment Decisions of Soft-tissue Sarcomas Patients
|
N/A | |
Recruiting |
NCT04452058 -
CT-based Radiomic Algorithm for Assisting Surgery Decision and Predicting Immunotherapy Response of NSCLC
|
||
Recruiting |
NCT04511481 -
Deep Learning Magnetic Resonance Imaging Radiomic Predict Platinum-sensitive in Patients With Epithelial Ovarian Cancer
|
||
Active, not recruiting |
NCT06140823 -
Prospective Validation of Liver Cancer Risk Computation (LIRIC) Models
|